Implication of fermentable carbohydrates targeting the gut microbiota on conjugated linoleic acid production in high-fat-fed mice

Céline Druart¹, Audrey M. Neyrinck¹, Evelyne M. Dewulf¹, Fabienne C. De Backer¹, Sam Possemiers², Tom Van de Wiele², Frédéric Moens³, Luc De Vuyst³, Patrice D. Cani¹, Yvan Larondelle⁴ and Nathalie M. Delzenne¹*¹

¹Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
²Laboratory of Microbial Ecology and Technology (LabMET), Ghent University, Ghent, Belgium
³Research Group of Industrial Microbiology and Food Biotechnology (IMDO), Department of Bioengineering Sciences, Vrije Universiteit Brussel, Brussels, Belgium
⁴Institut des Sciences de la Vie, Université catholique de Louvain, Louvain-la-Neuve, Belgium

(Submitted 11 July 2012 – Final revision received 19 December 2012 – Accepted 19 December 2012 – First published online 18 March 2013)

Abstract

In vitro experiments have shown that isolated human gut bacteria are able to metabolise PUFA into conjugated PUFA like conjugated linoleic acids (CLA). The hypothesis of the present paper was that high-fat (HF) diet feeding and supplementation with fermentable carbohydrates that have prebiotic properties modulate the in vitro production of CLA by the mouse gut microbiota. Mice were treated for 4 weeks as follows: control (CT) groups were fed a standard diet; HF groups were fed a HF diet rich in linoleic acid (18:2n-6); the third groups were fed with the HF diet supplemented with either inulin-type fructans (HF-ITF) or arabinoxylans (HF-Ax). HF diet feeding increased rumenic acid (cis-9,trans-11-18:2 CLA) content both in the caecal and liver tissues compared with the CT groups. ITF supplementation had no major effect compared with the HF diet whereas Ax supplementation increased further rumenic acid (cis-9,trans-11-18:2 CLA) in the caecal tissue. These differences between both prebiotics may be linked to the high fat-binding capacity of Ax that provides more substrates for bacterial metabolism and to differential modulation of the gut microbiota (specific increase in Roseburia spp. in HF-Ax v. HF). In conclusion, these experiments supply the proof of concept that the mouse gut microbiota produces CLA in vivo, with consequences on the level of CLA in the caecal and liver tissues. We postulate that the CLA-producing bacteria could be a mediator to consider in the metabolic effects of both HF diet feeding and prebiotic supplementation.

Key words: Conjugated linoleic acids; Gut microbiota; High-fat diet; Prebiotic supplementation

Conjugated linoleic acids (CLA) are a group of positional and geometric isomers of linoleic acid (LA; cis-9,cis-12-18:2) characterised by the presence of conjugated double bounds with cis or trans configuration. Some CLA isomers have demonstrated interesting biological effects such as anti-carcinogenic, anti-adipogenic, anti-atherogenic or anti-obesity properties¹,². In contrast, in certain conditions, some CLA isomers can also exert potentially negative effects such as insulin resistance and steatosis³–⁵. In humans, the main dietary sources of CLA are dairy products and meat derived from ruminant animals. The main CLA isomer found in these products is the isomer cis-9,trans-11-18:2, called rumenic acid (representing 75 to 90% of total CLA found in dairy products)⁶–⁹. CLA isomers are intermediates of the biohydrogenation pathway of LA carried out by rumen bacteria, leading finally to a SFA, stearic acid (18:0)⁷–⁹. It has been proposed that bacterial reduction of PUFA is a mechanism of protection against the toxicity of PUFA. Indeed, some PUFA prevent bacterial growth¹⁰,¹¹. The biohydrogenation pathway also leads to the production of other intermediates among which vaccenic acid (trans-11-18:1) is the most important. All biohydrogenation intermediates can partly escape from the rumen and be absorbed later in the ruminant intestine. Once in the animal tissues, they can be stored or further metabolised. Vaccenic acid (trans-11-18:1) can notably be desaturated into rumenic acid (cis-9,trans-11-18:2 CLA).

Abbreviations: α-LnA, α-linolenic acid; Ax, arabinoxylans; CLA, conjugated linoleic acid; CT, control; DPA, docosapentaenoic acid; FAME, fatty acid methyl esters; FBC, fat-binding capacity; HF, high-fat; ITF, inulin-type fructans; LA, linoleic acid; qPCR, quantitative PCR; SCD-1, stearoyl-CoA desaturase-1.

* Corresponding author: Professor Nathalie M. Delzenne, fax +32 2 764 73 59, email nathalie.delzenne@uclouvain.be

https://doi.org/10.1017/S0007114513000123
through the activity of a Δ9 desaturase enzyme (also called stearoyl-CoA desaturase-1; SCD-1)\(^{(12-14)}\).

The vast number of micro-organisms (10\(^{14}\) bacteria) in the human gut creates a large metabolic potential to take into account in host physiology\(^{(15)}\). Based on the biohydrogenation pathway observed in the rumen, some authors have proposed a similar pathway occurring in mammalian gut microbiota\(^{(16,17)}\). Furthermore, several arguments support a role of the gut microbiota in the endogenous production of CLA isomers. First, in vitro experiments have shown that several gut bacteria isolated from rodents or humans are able to metabolise LA into CLA isomers and vaccenic acid\(^{(18)}\). The three major genera including bacteria able to produce CLA and vaccenic acid in mice gut are \textit{Bifidobacteria} spp.\(^{(10,19)}\), \textit{Lactobacillus} spp.\(^{(20)}\) and \textit{Roseburia} spp.\(^{(21)}\). Second, the enzyme able to transform LA into CLA isomers, called linoleate isomerase, was sequenced in some \textit{Bifidobacterium} spp.\(^{(23)}\), two bacterial genera found in the gut microbiota. Third, \textit{Wall et al.}\(^{(23)}\) have shown that the fatty acid composition in host tissues was modified (including an increase of rumenic acid; cis-9, trans-11-18:2 CLA) after co-administration of a probiotic strain (\textit{Bifidobacterium breve}) and LA in mice. Finally, another interesting study showed that increasing the amount of LA in the diet increased the tissue content of CLA isomers in conventional rats (with a normal gut microbiota) but not in germ-free rats (lacking gut microbiota)\(^{(24)}\).

Alterations in the composition and/or activity of gut microbiota – known as dysbiosis – has been proposed to contribute to the development of obesity and associated metabolic disorders including low-grade inflammation, diabetes and dyslipidaemia\(^{(25)}\). We have previously shown that a high-fat (HF) diet leading to obesity and diabetes changes gut bacterial composition\(^{(26-29)}\). The interactions between gut microbiota and host are, at least in part, mediated by metabolites produced by gut microbes. For example, metabolites such as SCFA – mainly produced during the fermentation of non-digestible carbohydrates by saccharolytic bacteria – are able to be used both as metabolic substrates and regulators in host tissues\(^{(30,31)}\). In the present studies, we postulated that CLA isomers endogenously produced upon metabolic cooperation between the gut microbiota and host intestinal and liver tissues can be a new kind of metabolites susceptible to regulate host metabolism.

Prebiotics are non-digestible carbohydrates allowing the selective stimulation of growth and/or activity(ies) of one or a limited number of microbial genus(era)/species in the gut microbiota that confer(s) health benefits to the host\(^{(32)}\). Several studies have repeatedly shown that inulin-type fructans (ITF), non-digestible carbohydrates extracted from chicory root, are able to counteract obesity (diet or genetic induced) in rodents\(^{(33-37)}\). On the other hand, arabinoxylans (Ax) are the most important non-digestible carbohydrates present in wheat and represent a new class of potential prebiotics\(^{(38)}\). We have recently shown that the supplementation of either ITF or a concentrate of water-extractable high-molecular-weight Ax in the diet counteracted HF-induced gut dysbiosis together with an improvement in obesity\(^{(28,29)}\). We decided to treat mice with a HF diet and prebiotics (ITF or Ax) in order to evaluate the potential impact of these nutritional modulations of gut bacterial composition on fatty acid profile and in particular CLA isomer profile in the target host tissues (intestines and liver).

### Experimental methods

#### Animals and diets

We performed two experiments using the same conditions. Male C57Bl6/J mice (Charles River Laboratories) aged 9 weeks at the beginning of the experiments were housed in a controlled environment (12 h daylight cycle, lights off at 18.00 hours) with free access to diet and water. After 1 week of acclimatisation, the mice were separated into three groups (eight mice per group; four mice per cage). In the first experiment, mice were fed either with a control (CT) diet (AO4; SAFE) or a HF diet (D12492; Research Diets) or the HF diet and a supplementation of inulin-type fructans (ITF; 0·2 g/d per mouse of oligofructose provided by Orafti). In the second experiment, mice were fed either with the CT diet (AO4; SAFE), or the HF diet (D12492; Research Diets) or the HF diet and a supplementation of arabinoxyxsans (Ax; 0·2 g/d per mouse of Naxus provided by BioActor). Dietary treatments lasted for 4 weeks. Food intake was recorded taking into account spillage twice per week. The HF diet contained 60 % lipids, 20 % proteins and 20 % carbohydrate as energy content. The HF diet provided (per 100 g): 35 g fat (soyabean oil and lard), 9 g sucrose, 16 g maltodextrin, 26 g proteins and 6·5 g cellulose (according to the manufacturer’s information). We analysed the fatty acid profile of the CT diet and HF diet by GC–flame ionisation detector (see Table 1). All mouse experiments were approved by and performed in accordance with the guidelines of the local ethics committee. Housing conditions were specified by the Belgian Law of 6 April 2010 regarding the protection of laboratory animals (agreement no. LA1230 314).

#### Tissue samples

After 4 weeks of treatment and a 6 h period of fasting, mice were anaesthetised by intraperitoneal injection of ketamine (100 mg/kg; Anesketin; Eurovet) and xylazine (10 mg/kg; Rompun; Bayer Belgium). The liver, colon and caecum were carefully collected and frozen in liquid N\(_2\) before storage at \(-80^\circ\)C. The caecal content was collected and frozen for further microbial analysis. Data related to body weight, body weight gain and tissue weights are presented in Supplemental Table 1.

#### Fat-binding capacity analysis

The fat-binding capacity (FBC) of ITF and Ax was analysed according to an \textit{in vitro} method of lipid adsorption described by No \textit{et al.}\(^{(39)}\). We tested in parallel starch as a negative control and chitosan (Kionutrine-Cs™; KitoZyme S.A.) as a positive control.

#### Gut microbiota analysis

To study the gut microbiota composition, the QIAamp DNA stool mini kit (Qiagen) was used according to the
manufacturer's instructions to extract the metagenomic DNA from the caecal content of all mice. To analyse the quantitative effect of the different treatments on the composition of the gut microbiota, quantitative PCR (qPCR) was performed. qPCR for total bacteria and specific qPCR for *Bifidobacterium* spp., *Lactobacillus* spp. and *Roseburia* spp. were performed as reported previously (28,29,40). All qPCR were performed with an ABI PRISM 7000 Sequence Detection System (Applied Biosystems) using SYBR-Green (Mesa Fast qPCR™; Eurogentec) for detection. Ribosomal protein L19 (RPL19) RNA was chosen as the housekeeping gene to normalise the data, and further analysed according to the 2\(^{-\Delta \Delta C_t}\) method (41).

### Table 1. Fatty acid profile of the standard AO4 (control; CT) diet and the high-fat (HF) diet (g fatty acid/kg diet)

<table>
<thead>
<tr>
<th>Fatty Acid</th>
<th>CT diet</th>
<th>HF diet</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 : 0</td>
<td>0·045</td>
<td>2·887</td>
</tr>
<tr>
<td>cis-9-14 : 1</td>
<td>n.d.</td>
<td>0·070</td>
</tr>
<tr>
<td>15 : 0</td>
<td>0·009</td>
<td>0·168</td>
</tr>
<tr>
<td>16 : 0</td>
<td>1·186</td>
<td>50·047</td>
</tr>
<tr>
<td>cis-9-16 : 1</td>
<td>0·054</td>
<td>4·178</td>
</tr>
<tr>
<td>17 : 0</td>
<td>0·010</td>
<td>0·809</td>
</tr>
<tr>
<td>18 : 0</td>
<td>0·155</td>
<td>26·072</td>
</tr>
<tr>
<td>trans-9-18 : 1</td>
<td>0·018</td>
<td>0·696</td>
</tr>
<tr>
<td>trans-11-18 : 1</td>
<td>n.d.</td>
<td>0·647</td>
</tr>
<tr>
<td>cis-9-18 : 1</td>
<td>1·203</td>
<td>79·952</td>
</tr>
<tr>
<td>cis-11-18 : 1</td>
<td>0·079</td>
<td>5·310</td>
</tr>
<tr>
<td>18 : 2n-6</td>
<td>2·957</td>
<td>62·087</td>
</tr>
<tr>
<td>20 : 0</td>
<td>0·018</td>
<td>0·462</td>
</tr>
<tr>
<td>18 : 3n-3</td>
<td>0·218</td>
<td>4·496</td>
</tr>
<tr>
<td>cis-9,trans-11-18 : 2</td>
<td>n.d.</td>
<td>0·387</td>
</tr>
<tr>
<td>trans-10,cis-12-18 : 2</td>
<td>n.d.</td>
<td>0·303</td>
</tr>
<tr>
<td>20 : 3n-3</td>
<td>0·002</td>
<td>0·367</td>
</tr>
<tr>
<td>20 : 4n-6</td>
<td>0·007</td>
<td>0·591</td>
</tr>
<tr>
<td>20 : 5n-3</td>
<td>0·036</td>
<td>0·029</td>
</tr>
<tr>
<td>22 : 5n-3</td>
<td>0·008</td>
<td>0·186</td>
</tr>
<tr>
<td>22 : 6n-3</td>
<td>0·054</td>
<td>0·065</td>
</tr>
<tr>
<td>Total</td>
<td>6·059</td>
<td>239·568</td>
</tr>
</tbody>
</table>

n.d., Not detectable, below the level of detection.

### Real-time quantitative PCR

Total RNA was extracted from the liver and colon using the TriPure isolation reagent (Roche Diagnostics Belgium). cDNA was prepared by reverse transcription from 1 μg of total RNA using the Kit Reverse Transcription System (Promega). Real-time PCR was performed with the Setp OnePlus™ real-time PCR system and software (Applied Biosystems) using SYBR-Green (Mesa Fast qPCR™; Eurogentec) for detection. Ribosomal protein L19 (RPL19) RNA was chosen as the housekeeping gene to normalise the data, and further analysed according to the 2\(^{-\Delta \Delta C_t}\) method (41).

### Statistical analysis

Results are presented as mean values with their standard errors. Statistical significance of difference between groups was assessed by one-way ANOVA followed by Tukey’s post hoc multiple comparison test (GraphPad Prism Software). *P*<0·05 was considered as statistically significant. Values with unlike superscript letters are significantly different (*P*<0·05) according to Tukey’s post hoc ANOVA statistical analysis.

### Results

**Modulation of number of conjugated linoleic acid-producing bacteria in caecal content by high-fat diet and additional prebiotic treatments**

In both experiments, the HF diet decreased the number of CLA-producing bacteria, calculated as the sum of the three most cited genera able to produce CLA (*Bifidobacterium* spp., *Roseburia* spp., *Lactobacillus* spp.) (Table 2). Prebiotic supplementations counteracted the HF diet-induced decrease of CLA-producing bacteria: ITF supplementation restored the number of CLA-producing bacteria to the CT level whereas following Ax supplementation, the number of CLA-producing bacteria increased but did not reach the CT value (Table 2). The bacterial genera modulated by each prebiotic were different (Table 2). ITF and Ax both increased *Bifidobacterium* spp. compared with the HF diet, but the bifidogenic effect of ITF was more important than the one of Ax. ITF decreased *Roseburia* spp. and *Lactobacillus* spp. compared with the HF diet, whereas Ax increased *Roseburia* spp. without
modulation of Lactobacillus spp. compared with the HF diet. It is worth noting that prebiotic supplementations did not change the number of total caecal bacteria compared with HF groups (Table 2).

**Modulation of profile of bacterial derived n-6 PUFA in the liver by high-fat diet and additional prebiotic treatments**

In the caecal tissue and in the liver, changes in LA (cis-9, cis-12-18:2), rumenic acid (cis-9, trans-11-18:2 CLA) and vaccenic acid (trans-11-18:1), the three major fatty acids of the linoleic biohydrogenation pathway, occurred upon dietary manipulation. The amount of total fatty acids, LA (cis-9, cis-12-18:2) and n-6 PUFA metabolites (including bacterial derived metabolites) are presented in Fig. 1 (liver tissue) and Fig. 2 (caecal tissue).

In the liver, we observed (in both experiments) the presence of rumenic acid (cis-9, trans-11-18:2 CLA) and vaccenic acid (trans-11-18:1) in the CT groups, despite the fact that these fatty acids were undetectable in the CT diet (Table 1). The hepatic total fatty acids and LA (cis-9, cis-12-18:2) contents were not significantly modified in the HF groups compared with the CT groups, whereas HF diet feeding increased arachidonic acid (20:4n-6) and tended to increase rumenic acid (cis-9, trans-11-18:2 CLA) (Fig. 1) and Supplemental Table 2. Regarding vaccenic acid (trans-11-18:1), its content was not modified by the HF diet in the first experiment whereas it decreased in the second experiment (Fig. 1 and Supplemental Table 2). Concerning the n-3 PUFA profile, the HF diet did not significantly change α-linolenic acid (α-LnA; 18:3n-3), docosapentaenoic acid (DPA; 22:5n-3) and DHA (22:6n-3) contents but decreased EPA (20:5n-3) (Fig. 3).

Prebiotic supplementations (both ITF and Ax) had no significant effect on total fatty acids and the n-6 PUFA profile compared with the HF diet but induced changes in the n-3 profile. The level of EPA (20:5n-3), DPA (22:5n-3) and DHA (22:6n-3) was not modified by ITF supplementation whereas Ax supplementation decreased EPA (20:5n-3) and DPA (22:5n-3) and tended to decrease DHA (22:6n-3) compared with HF diet feeding (Fig. 3).

In the caecal tissue, as observed in the liver, we detected and quantified rumenic acid (cis-9, trans-11-18:2 CLA) and vaccenic acid (trans-11-18:1) in the CT groups (Fig. 2). Regarding the modifications of the n-6 PUFA profile by HF diet feeding and prebiotic supplementations, we observed different effects between experiments 1 and 2.

In experiment 1, HF diet feeding did not significantly change total fatty acids, LA (cis-9, cis-12-18:2) and rumenic acid (cis-9, trans-11-18:2 CLA) content, but HF diet feeding increased the arachidonic acid (20:4n-6) content (produced in host tissue from LA) and the vaccenic acid (trans-11-18:1) content (a bacterial metabolite of LA) (Fig. 2). Furthermore, ITF supplementation had no additional effects compared with the ones observed following HF diet feeding, except that the relative proportion of rumenic acid (cis-9, trans-11-18:2 CLA) (expressed as percentage of the total fatty acids identified) was increased by ITF compared with the HF diet (P=0.05; t test) (Supplemental Table S3).

In experiment 2, HF diet feeding tended to increase total fatty acids and LA (cis-9, cis-12-18:2) contents compared with the CT diet (Fig. 2). Both contents in the HF group were 1.4-fold higher than the contents measured in the CT group. HF diet feeding significantly increased vaccenic acid (trans-11-18:1) content compared with the CT diet (Fig. 2). HF diet feeding did not significantly change the absolute content of rumenic acid (cis-9, trans-11-18:2 CLA) but significantly increased the relative proportion of rumenic acid (cis-9, trans-11-18:2 CLA) (results expressed as a percentage of the total fatty acids identified) (Supplemental Table S3). Total fatty acids and LA (cis-9, cis-12-18:2) content increased upon Ax supplementation (Fig. 2). The level in the HF-Ax group was 1.5 times higher than the amount measured in the HF group and two times higher than the amount measured in the CT group. Ax supplementation increased the rumenic acid (cis-9, trans-11-18:2 CLA) content (absolute content and relative proportion) compared with both the CT and HF groups (Fig. 2 and Supplemental Table S3). Ax supplementation

**Table 2. Gut microbiota analysis in the caecal content of mice after 4 weeks of dietary treatment**

*Mean values with their standard errors*

<table>
<thead>
<tr>
<th>Diet...</th>
<th>Experiment 1</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Experiment 2</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CT</td>
<td>HF</td>
<td>HF-ITF</td>
<td>CT</td>
<td>HF</td>
<td>HF-Ax</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
<td>SEM</td>
</tr>
<tr>
<td>Total bacteria</td>
<td>11.167</td>
<td>0.0877</td>
<td>10.559</td>
<td>0.0630</td>
<td>10.463</td>
<td>0.0523</td>
<td>10.565</td>
<td>0.1030</td>
<td>9.927</td>
<td>0.0484</td>
<td>10.086</td>
<td>0.0733</td>
</tr>
<tr>
<td>CLA-producing bacteria†</td>
<td>8.685</td>
<td>0.1080</td>
<td>7.245</td>
<td>0.0538</td>
<td>8.970</td>
<td>0.1490</td>
<td>8.488</td>
<td>0.0906</td>
<td>7.299</td>
<td>0.0459</td>
<td>7.966</td>
<td>0.1190</td>
</tr>
<tr>
<td>Bifidobacterium spp.</td>
<td>6.904</td>
<td>0.2220</td>
<td>6.809</td>
<td>0.1400</td>
<td>8.967</td>
<td>0.1500</td>
<td>7.171</td>
<td>0.0413</td>
<td>7.071</td>
<td>0.0295</td>
<td>7.873</td>
<td>0.1320</td>
</tr>
<tr>
<td>Lactobacillus spp.</td>
<td>8.665</td>
<td>0.0999</td>
<td>6.768</td>
<td>0.0595</td>
<td>6.531</td>
<td>0.1080</td>
<td>8.388</td>
<td>0.1170</td>
<td>6.856</td>
<td>0.1020</td>
<td>6.765</td>
<td>0.0425</td>
</tr>
<tr>
<td>Roseburia spp.</td>
<td>8.646</td>
<td>0.0999</td>
<td>6.422</td>
<td>0.1720</td>
<td>5.661</td>
<td>0.0336</td>
<td>7.521</td>
<td>0.0949</td>
<td>5.326</td>
<td>0.1390</td>
<td>6.920</td>
<td>0.1300</td>
</tr>
</tbody>
</table>

CT, control; HF, high-fat; HF-ITF, high-fat diet supplemented with inulin-type fructans; HF-Ax, high-fat diet supplemented with arabinoxylans; CLA, conjugated linoleic acids.

**Modulation of profile of bacterial derived n-6 PUFA in the caecum by high-fat diet and additional prebiotic treatments**

In the caecal tissue and in the liver, changes in LA (cis-9, cis-12-18:2), rumenic acid (cis-9, trans-11-18:2 CLA) and vaccenic acid (trans-11-18:1) in the CT groups (Fig. 2). Regarding the modifications of the n-6 PUFA profile by HF diet feeding and prebiotic supplementations, we observed different effects between experiments 1 and 2.

In experiment 1, HF diet feeding did not significantly change total fatty acids, LA (cis-9, cis-12-18:2) and rumenic acid (cis-9, trans-11-18:2 CLA) content, but HF diet feeding increased the arachidonic acid (20:4n-6) content (produced in host tissue from LA) and the vaccenic acid (trans-11-18:1) content (a bacterial metabolite of LA) (Fig. 2). Furthermore, ITF supplementation had no additional effects compared with the ones observed following HF diet feeding, except that the relative proportion of rumenic acid (cis-9, trans-11-18:2 CLA) (expressed as percentage of the total fatty acids identified) was increased by ITF compared with the HF diet (P=0.05; t test) (Supplemental Table S3).

In experiment 2, HF diet feeding tended to increase total fatty acids and LA (cis-9, cis-12-18:2) contents compared with the CT diet (Fig. 2). Both contents in the HF group were 1.4-fold higher than the contents measured in the CT group. HF diet feeding significantly increased vaccenic acid (trans-11-18:1) content compared with the CT diet (Fig. 2). HF diet feeding did not significantly change the absolute content of rumenic acid (cis-9, trans-11-18:2 CLA) but significantly increased the relative proportion of rumenic acid (cis-9, trans-11-18:2 CLA) (results expressed as a percentage of the total fatty acids identified) (Supplemental Table S3). Total fatty acids and LA (cis-9, cis-12-18:2) content increased upon Ax supplementation (Fig. 2). The level in the HF-Ax group was 1.5 times higher than the amount measured in the HF group and two times higher than the amount measured in the CT group. Ax supplementation increased the rumenic acid (cis-9, trans-11-18:2 CLA) content (absolute content and relative proportion) compared with both the CT and HF groups (Fig. 2 and Supplemental Table S3). Ax supplementation...
had no additional effect on the vaccenic acid (trans-11-18:1) content compared with the effect observed upon HF diet feeding.

In addition to the changes observed in the n-6 PUFA profile, the n-3 PUFA profile was also modified after the different dietary treatments (Fig. 4). α-LnA (18:3n-3) content tended to be increased after HF diet feeding. The level in the HF group was about 2-fold higher than the amount measured in the CT group in both experiments. We also observed changes in the level of long- and very-long chain n-3 PUFA, consisting of a decreased EPA (20:5n-3) content and an increased DPA (22:5n-3) content following HF diet feeding whereas

Fig. 1. Total fatty acids (FA) (A), linoleic acid (LA; 18:2n-6) (B) and n-6 PUFA metabolites arachidonic acid (AA; 20:4n-6) (C), rumenic acid (RA; cis-9,trans-11-18:2) (D) and vaccenic acid (VA; trans-11-18:1) (E) in the liver tissue of mice after 4 weeks of dietary treatment: control (CT) diet; high-fat (HF) diet; or HF diet supplemented with inulin-type fructans (HF-ITF) or arabinoxylans (HF-Ax). Values are means, with their standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P<0.05; Tukey’s post hoc ANOVA statistical analysis).
DHA (22:6n-3) content was not modified upon HF diet feeding (Fig. 4). ITF supplementation had no additional effect on the n-3 PUFA profile (α-LNA, EPA, DPA and DHA) compared with HF diet feeding (Fig. 4). Ax supplementation had no additional effect on the n-3 PUFA profile (α-LNA, EPA, DPA and DHA) compared with HF diet feeding (Fig. 4). Ax supplementation further increased α-LNA (18:3n-3) acid content, this increase appearing significant as compared with the CT group (Fig. 4). Ax supplementation had no additional effect on EPA (20:5n-3) content but it decreased the relative proportion of DPA (22:5n-3) and DHA (22:6n-3) compared with HF diet feeding (Supplemental Table 3).

**Effect of high-fat diet feeding and additional prebiotic treatments supplementation on stearoyl-CoA desaturase-1 mRNA expression and activity in the liver and caecal tissue**

We observed changes in the rumenic acid (cis-9,trans-11-18:2 CLA) content in the caecal tissue and in the liver after HF diet feeding. Rumenic acid (cis-9,trans-11-18:2 CLA) may be produced directly by bacteria, or indirectly in host tissues from vaccenic acid (trans-11-18:1). In order to evaluate the contribution of host metabolism to the changes in rumenic

---

**Fig. 2.** Total fatty acids (FA) (A), linoleic acid (LA; 18:2n-6) (B) and n-6 PUFA metabolites arachidonic acid (AA; 20:4n-6) (C), rumenic acid (RA; cis-9,trans-11-18:2) (D) and vaccenic acid (VA; trans-11-18:1) (E) in the caecal tissue of mice after 4 weeks of dietary treatment: control (CT) diet; high-fat (HF) diet; or HF diet supplemented with inulin-type fructans (HF-ITF) or arabinoxylans (HF-Ax). Values are means, with their standard errors represented by vertical bars. a,b Mean values with unlike letters were significantly different (P<0.05; Tukey’s post hoc ANOVA statistical analysis).
acid (cis-9, trans-11-18: 2 CLA) content observed in the caecal tissue and in the liver, we measured SCD-1 mRNA expression and estimated its activity in intestinal segments and in the liver. The expression of SCD-1 mRNA was at least 20-fold higher in the liver than in the different intestinal segments (data not shown). As shown in Table 3, SCD-1 mRNA expression was decreased by the HF diet in the liver and the colon tissue in both experiments. Both prebiotic supplementations had no major effect on SCD-1 mRNA expression in the liver and in the colon compared with the HF diet, except that Ax further decreased mRNA expression in the liver compared with the HF diet.

In order to strengthen the SCD-1 mRNA expression results, we also estimated the SCD-1 activity by calculating ‘desaturation ratios’. In both experiments, HF diet feeding decreased the cis-9-14:1/14:0 and cis-9-16:1/16:0 ratios in the liver and in the caecal tissue whereas the cis-9-18:1/18:0 ratio was unchanged in these tissues (Table 3). Prebiotic supplementations had no additional effect compared with the effects of the HF diet (Table 3).

**Fat-binding capacity of arabinoxylans and inulin-type fructans**

As shown in Fig. 5, we obtained a FBC of 150% for starch used as the negative control and a FBC of 245% for chitosan used as the positive control. The FBC of ITF was weak (180%) whereas Ax had a much higher FBC (403%). This result shows the high FBC of Ax.

**Discussion**

Gut microbiota composition/activity can influence host physiology. The gut microbiota interacts with the host in...
part through the production of metabolites, such as SCFA or bile acid metabolites\(^{(25)}\). Bacteria can also produce lipophilic metabolites, in particular conjugated isomers of LA (CLA\(^{(10,16,18,42–44)}\)) and conjugated isomers of \(\alpha\)-LnA\(^{(44–47)}\).

The main objective of our experiments was to study if the gut microbiota modulates the production of CLA in vivo upon HF diet feeding and to evaluate the potential effect of prebiotic supplementations in changing the amount of CLA produced by modulation of the gut microbiota composition/activity.

Although rumenic acid (cis-9,trans-11-18:2 CLA) and vaccenic acid (trans-11-18:1) were undetectable in the CT diet, these fatty acids were present both in the liver and the caecal tissue of control mice, strongly supporting their ‘endogenous’ production by the gut microbiota through the biohydrogenation pathway of LA. The gut microbiota composition of HF-fed mice was different from CT mice: for instance, the counts of bacterial groups typically associated with CLA production were decreased and this was mostly due to a decrease in Lactobacillus spp. However, the quantity of the substrate (LA; 18:2n-6) available for bacterial metabolism is much higher in the HF diet compared with the CT diet (the HF diet contains twenty times more LA than the CT diet). Interestingly, although the counts of CLA-producing bacteria were decreased upon HF diet feeding, we observed an increase in rumenic acid (cis-9,trans-11-18:2 CLA) and in vaccenic acid (trans-11-18:1) in the caecal tissue. This observation suggests that the quantity of substrate available is the rate-limiting factor for CLA synthesis by gut microbiota in control conditions. One explanation may be that nearly all the fatty acids are absorbed in the jejunum and ileum (proximal part) in the control conditions (CT diet), leading to very small quantities of lipids reaching the caecum. In this way, we can assume that the amount of LA (18:2n-6) available for CLA synthesis in the caecum, where bacteria are the

![Fig. 4. \(\alpha\)-Linolenic acid (\(\alpha\)-LnA; 18:3n-3) (A) and \(n\)-3 PUFA metabolites EPA (20:5n-3) (B), docosapentaenoic acid (DPA; 22:5n-3) (C) and DHA (22:6n-3) (D) in the caecal tissue of mice after 4 weeks of dietary treatment: control (CT) diet; high-fat (HF) diet; or HF diet supplemented with inulin-type fructans (HF-ITF) or arabinoxylans (HF-Ax). Values are means, with their standard errors represented by vertical bars. \(a,b\) Mean values with unlike letters were significantly different (\(P<0.05\); Tukey’s post hoc ANOVA statistical analysis).](https://www.cambridge.org/core/core)
Table 3. Stearoyl-CoA desaturase-1 (SCD-1) mRNA expression and activity in the liver and intestinal tissues of mice after 4 weeks of dietary treatment* (Mean values with their standard errors)

<table>
<thead>
<tr>
<th>Diet</th>
<th>Experiment 1</th>
<th>Experiment 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>CE</td>
<td>CE</td>
<td>CE</td>
</tr>
<tr>
<td>SCD-1 mRNA</td>
<td>Mean</td>
<td>SEM</td>
</tr>
<tr>
<td>Colon</td>
<td>1.000a</td>
<td>0.173</td>
</tr>
<tr>
<td>Liver</td>
<td>14:1/14:0</td>
<td>0.0779a</td>
</tr>
<tr>
<td>Liver</td>
<td>16:1/16:0</td>
<td>0.207a</td>
</tr>
<tr>
<td>Liver</td>
<td>18:1/18:0</td>
<td>3.104a</td>
</tr>
<tr>
<td>Caecal tissue</td>
<td>14:1/14:0</td>
<td>0.0528a</td>
</tr>
<tr>
<td>Caecal tissue</td>
<td>16:1/16:0</td>
<td>0.238a</td>
</tr>
<tr>
<td>Caecal tissue</td>
<td>18:1/18:0</td>
<td>3.903</td>
</tr>
<tr>
<td>Caecal tissue</td>
<td>19:1/19:0</td>
<td>5.601</td>
</tr>
<tr>
<td>SCD-1 activity</td>
<td>Mean</td>
<td>SEM</td>
</tr>
<tr>
<td>Colon</td>
<td>0.00046</td>
<td>0.00012</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00059</td>
<td>0.00015</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00085</td>
<td>0.00016</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00103</td>
<td>0.00017</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00139</td>
<td>0.00020</td>
</tr>
<tr>
<td>Colon</td>
<td>0.00046</td>
<td>0.00012</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00059</td>
<td>0.00015</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00085</td>
<td>0.00016</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00103</td>
<td>0.00017</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00139</td>
<td>0.00020</td>
</tr>
</tbody>
</table>

Note: Mean values within a row with unlike superscript letters were significantly different (P<0.05; Tukey's post hoc test).

* SCD-1 activity was estimated by calculation of the 'desaturation ratio', the ratio between the MUFA produced by the SCD-1 and their respective SFA, the substrate of the SCD-1.
linoleate isomerase activity and thus the highest capacity to increased upon Ax supplementation, possess the highest of the gut microbiota. Indeed, supplementation could be explained by the different modulation content and vaccenic acid (trans-11-18:1) significantly increased the rumenic acid (cis-9,trans-11-18:2 CLA) production. Another important difference is that Ax, but not ITF, decreased Roseburia spp. whereas Ax increased this bacterial genus compared with HF diet feeding.

Regarding the effects of prebiotic supplementations on the host tissue fatty acid profiles, we observed that Ax, but not ITF, significantly increased the rumenic acid (cis-9,trans-11-18:2 CLA) content and tended to increase the LA (18:2n-6) content and vaccenic acid (trans-11-18:1) content in the caecal tissue. This difference between the two prebiotic supplementations could be explained by the different modulation of the gut microbiota. Indeed, Roseburia spp., that were increased upon Ax supplementation, possess the highest linoleate isomerase activity and thus the highest capacity to produce CLA and other metabolites of LA. In fact, this observation supports the idea that the presence of Roseburia spp. is more important than the presence of Bifidobacterium spp. for CLA production. Another important difference between the two prebiotics used in our studies is their capacity to bind dietary fat. In fact, in vitro data showed that ITF have a weak FBC whereas Ax have a strong FBC.

Ax supplementation could thus also promote CLA production by increasing LA (18:2n-6) availability in the lower part of the gut. Indeed, we observed that Ax increased total fatty acid, LA (18:2n-6) and α-LnA (18:3n-5) contents in the caecal tissue compared with HF diet feeding whereas ITF supplementation had no effect on these fatty acid contents.

Even if we observed a higher proportion of rumenic acid (cis-9,trans-11-18:2 CLA) and vaccenic acid (trans-11-18:1) in the liver following HF diet feeding, the further increase of these two fatty acids upon prebiotic supplementations was observed in the caecum but not in the liver. This observation supports the idea that modulation of the bacterial metabolites of LA is restricted to intestinal tissues, the tissues situated near the production site of CLA. However, we have previously found an increase in rumenic acid (cis-9,trans-11-18:2 CLA) in adipose tissue after Ax supplementation, suggesting that the increase in rumenic acid (cis-9,trans-11-18:2 CLA) after Ax supplementation is not restricted to intestinal tissue but also concerns tissues situated far from the intestine. In view of this, we postulate that rumenic acid (cis-9,trans-11-18:2 CLA) produced by the gut microbiota can have some systemic effects, in addition to the local effects in intestinal tissue. However, due to the rather low increase in vaccenic acid and rumenic acid content in host tissue, the size of the effect attributed to these changes in the fatty acid profile should be interpreted cautiously. Even if the changes in vaccenic acid and rumenic acid content in host tissue are relatively modest, a metabolic effect could be expected since in the cow, a dose as small as 0.05% of trans-10,cis-12-18:2 CLA is able to inhibit the mammary biosynthesis of milk fat by a down-regulation of the enzymes implicated in mammary lipid synthesis. The challenging question is now to identify whether CLA are produced in the upper part of the gastrointestinal tract and absorbed by the classical route of intestinal fat absorption or if CLA are only produced by the dense gut microbiota situated in the caecum and absorbed by an unidentified mechanism of absorption.

In view of the metabolic pathways known in ruminants as well as the data obtained in vitro and in our studies, we propose a mechanism of CLA synthesis in which the gut microbiota and the host are involved in symbiosis (Fig. 6). We know that SCD-1 activity in host tissues can influence the CLA content in these tissues. To identify the relative contribution of gut microbiota metabolism as compared with the host metabolism involved in the CLA content changes, we measured SCD-1 expression and estimated its activity in host tissue. SCD-1 mRNA expression was decreased by the HF diet in the liver and the colon tissue in both experiments. A way commonly used in the literature to estimate the SCD-1 activity is to calculate the ‘desaturation ratio’, which means the ratio between MUFA (myristoleic acid, palmitoleic acid, oleic acid) produced by the SCD-1 and corresponding SFA substrates (myristic acid, palmitic acid and stearic acid, respectively). In both experiments, HF diet feeding decreased the cis-9,14:1/14:0 and cis-9,16:1/16:0 ratios in the liver and in the caecal tissue but had no effect on cis-9,18:1/18:0 in these tissues. Prebiotic supplementations had no additional effect compared with the effects of the HF diet. In general, HF diet feeding decreased SCD-1 mRNA expression and activity in the liver and in the caecal tissue without major effect of the prebiotic supplementation. Thus, the higher rumenic acid (cis-9,trans-11-18:2 CLA) content in the caecal tissue results from the modulation of the bacterial metabolism of LA rather than changes in host desaturase (SCD-1) expression and/or activity. Although there is strong evidence for an effect of the gut microbiota on the tissue
levels of rumenic acid (cis-9,trans-11-18:1; 2 CLA), a contribution of the endogenous host desaturase (SCD-1) activity cannot be ruled out. In ruminants, the majority of rumenic acid (cis-9,trans-11-18:2; 2 CLA) found in tissues results from the desaturation of a bacterial metabolite, vaccenic acid (trans-11-18:1), by SCD-1 in ruminant tissues (12). We may propose that the increase of rumenic acid (cis-9,trans-11-18:2; 2 CLA) observed in caecal tissue is the result of the desaturation by host SCD-1 enzyme of the high amount of vaccenic acid (trans-11-18:1) produced by the gut microbiota. It has already been reported that administration of commercial gut bacteria leads to changes in fatty acid profile in different endogenous tissues (for example, adipose tissue, liver and brain) (33,34). Wall et al. reported that supplementation with a CLA-producing bacteria (Bifidobacterium breve) (30,36) and LA (18:2n-6) not only increased rumenic acid (cis-9,trans-11-18:2; 2 CLA) content in murine tissues but also changed the n-3 PUFA profile (23). They observed an increase in both EPA (20:5n-3) and DHA (22:6n-3) contents in the large intestine and adipose tissue (23). In our studies, we observed that HF diet feeding decreased EPA (20:5n-3) content in the liver and caecal tissues and Ax supplementation further decreased EPA (20:5n-3) content in the liver. It is interesting to note that, even if α-LnA (18:3n-3) content was increased after Ax supplementation, EPA (20:5n-3) content did not increase after Ax supplementation although α-LnA (18:3n-3) is the precursor of very-long-chain n-3 PUFA. This observation is in favour of the requisition of the enzymes required for the synthesis of very-long-chain n-3 PUFA in another pathway such as the production of conjugated very-long-chain n-6 PUFA from CLA. Indeed, the production of conjugated very-long-chain n-6 PUFA from CLA has been described, and those metabolites could lead to interesting biological properties (15). In addition, it has also been shown that the activity of the enzymes implicated in very-long-chain PUFA synthesis (desaturase and elongase) is regulated by the nutritional status and by the composition of the dietary fat (56–58). Deficiency in essential fatty acids increases enzyme activity whereas consumption of essential fatty acids decreases enzyme activity. Therefore, the increase in α-LnA observed after Ax supplementation could decrease the activity of the enzymes implicated in the long-chain PUFA synthesis and contribute to the decrease in EPA content.

The analytical method used to analyse the fatty acid profile in tissue allowed us to quantify only rumenic acid (cis-9,trans-11-18:2; 2 CLA). This is the major CLA isomer produced by Bifidobacterium spp. (34,59); however, CLA are a large group of isomers and quantification of other isomers would be interesting since the literature indicates that the physiological effects of CLA are isomer specific (2,4,8,60,61). Finally, some bacteria isolated from the mammalian gut are also able to produce conjugated LnA in vitro (44,47) and some biological effects are now attributed to this other group of conjugated fatty acids (45,46,62,63). So, an analysis of conjugated LnA and even a global analysis of conjugated PUFA in host tissues would be an interesting perspective of our studies.

In conclusion, we showed for the first time that the gut microbiota of mice is able to produce CLA without any supplementation. We showed that HF diet feeding increased CLA content in host tissues by increasing substrate availability for the gut microbiota. Prebiotic supplementations further increased CLA content in the caecal tissue, by further increasing substrate availability and modulating the gut microbiota composition. Just as some papers have proposed that CLA production is a characteristic of probiotic bacteria (49,64), we propose that CLA production is a characteristic to take into account in the metabolic effects of non-digestible carbohydrates with prebiotic properties.
Supplementary material

To view supplementary material for this article, please visit https://dx.doi.org/10.1017/S0007114513000123

Acknowledgements

Financial support has been provided by grants from the Walloon Region (General Directory of Agriculture, convention D31–1107) and Fonds de la Recherche Scientifique (FRS-FNRS; no. 1.5-095-09F). P. D. C. is Research Associate from the FRS-FNRS, Belgium. F. M. and L. D. V. benefit from financial support by the Research Foundation – Flanders (Fonds Wetenschappelijk Onderzoek (FWO) – Vladeren) and the Research Council of the Vrije Universiteit Brussel. F. M. is the recipient of a PhD fellowship of the Research Foundation – Flanders (FWO – Vladeren). S. P. and T. V. D. W. performed and interpreted the data. E. D. W. designed the experiments, performed data collection and analysis, and technical support.

The authors thank Christine Turu and Eric Mignolet for their excellent technical assistance in the fatty acid profile analysis; and Barbara Pachikian, Laure Bindels, Amandine Everard, Lucie Geurts and Bouazza Es Saadi for helpful discussion and technical support.

C. D. performed data collection and analysis, interpreted the data and wrote the manuscript. A. N. M. designed the experiments, performed data collection and analysis, and interpreted the data. E. D. W. designed the experiments, and performed data collection and analysis. F. C. D. B. performed data collection. S. P. and T. V. D. W. performed and interpreted gut microbiota analysis. F. M. and L. D. V. participated to the gut microbiota analysis. P. D. C. performed the tissue sampling at the end of the experiment. N. M. D. planned and reviewed all experiments and manuscript preparation. A. M. N., P. D. C., N. M. D. and Y. L. provided intellectual input on the paper and reviewed the paper.

The authors declare no conflicts of interests.

References


